OncRef

Clinical Trial: NCT05089734

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Gilead Sciences
Information Provided By:Gilead Sciences
Last Update Posted:2026-05-07

Study Overview

Brief Summary

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).

Official Title

Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Biological: Sacituzumab Govitecan-hziy (SG)
  • Drug: Docetaxel

Other Study ID Numbers

  • GS-US-577-6153
  • jRCT2051220119
  • 2024-512148-50

Start Date (Actual)

2021-11-17

Primary Completion Date (Actual)

2023-11-29

Study Completion Date (Estimated)

2027-01

Enrollment (Actual)

603

Study Type

Interventional

Phase

Phase 3